Press "Enter" to skip to content

New patent for Astrazeneca Ab drug BYDUREON

0
Copyright © DrugPatentWatch. Originally published at New patent for Astrazeneca Ab drug BYDUREON

Annual Drug Patent Expirations for BYDUREON
Annual Drug Patent Expirations for BYDUREON

Bydureon is a drug marketed by Astrazeneca Ab and is included in two NDAs. It is available from one supplier. There are thirty-six patents protecting this drug.

BYDUREON drug price trends.

Drug patent litigation for BYDUREON.

This drug has nineteen patent family members in fourteen countries.

The generic ingredient in BYDUREON is exenatide. One supplier is listed for this compound. Additional details are available on the exenatide profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Astrazeneca Ab drug BYDUREON
Online Certificate Course

Decision-Making for Generic Drug Entry & Branded Drug Lifecycle Management

  • When will key drug patents expire?
  • How can I find, evaluate, and plan for generic market entry opportunities?
  • How can I find proprietary out-of-court settlements and deal terms?
DrugPatentWatch - Make Better Decisions